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Contrast M, designed for contrast agent applications in high fieldmagnetic
resonance imaging (H12L is based on a trimethylbenzene core bearing three methylene-diethylenetriamine-
N,N,N00,N00-tetraacetate moieties). Thanks to its appropriate size, the presence of two inner sphere water molecules
and a fast water exchange, Gd3L has remarkable proton relaxivities at high magnetic field (r1¼ 10.2 vs 3.0mMS1 sS1
for GdDOTA at 9.4 T, 37-C, in H2O). Here we report an in vivo MRI feasibility study, complemented with dynamic g
scintigraphic imaging and biodistribution experiments using the 153Sm-enriched analog. MRI experiments
were performed at 9.4 T in mice with Gd3L and the commercial contrast agent gadolinium(III)-1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetate (GdDOTA). Gd3L was well tolerated by the animals at the dose of
8mmolGdkgS1 body weight. Dynamic contrast enhanced (DCE) images showed considerably higher signal enhance-
ment in the kidney medulla and cortex after Gd3L injection than after GdDOTA injection at an identical dose. The
relaxation rates, DR1, were calculated from the IR TrueFISP data. During the excretory phase, the DR1 for various
tissues was similar for Gd3L and GdDOTA, when the latter was injected at a three-fold higher dose (24 vs
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enhanced; FLASH, fast low angle shot, fast gradient echo MRI method; FOV, field of view; CGd, gadolinium concentration; GdDOTA, gadoterate meglumine,
MR contrast agent; HSA, human serum albumin; IR, inversion recovery; i.v., intravenous; PK, pharmacokinetic; RARE, rapid acquisition and relaxation
ment, fast spin echo MRI method; ROI, region of interest; T1, spin-lattice relaxation time in MR; TE, echo time; TI, inversion time; TR, repetition time;
ISP, inversion recovery TrueFISP imaging.
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Figure 1.
Contrast M
MRI CONTRAST AGENTS FOR HIGH FIELD APPLICATIONSGd) for Gd3L relative to GdDOTA, thus the ratio of the relaxivities of the two compounds determined in vitro is retained
under in vivo conditions. They also indicate that the two inner sphere water molecules per Gd in Gd3L are not
substantially replaced by endogenous anions or other donor groups under physiological conditions. Gd3L has a
pharmacokinetics typical of small, hydrophilic complexes, involving fast renal clearance and no retention in the blood
pool. The dynamic g scintigraphic studies and the biodistribution experiments performed in Wistar rats with
153Sm-enriched *Sm3L are also indicative of a fast elimination via the kidneys. Copyright # 2008 John Wiley &
Sons, Ltd.
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In magnetic resonance imaging, higher field strength is
translated to a better sensitivity and greater spatial or temporal
resolution, which explains the current tendency to increase the
magnetic field in both clinical and experimental settings. While
today 1.5 T remains the predominant field strength in the clinics,
the 3 T magnet continues to gain market share. In experimental
animal studies, magnetic fields7.0 T are commonly applied (1).
The signal-to-noise ratio correlates in approximately linear
fashion with field strength, thus by increasing the field, the time
needed to acquire satisfactory images can be substantially
reduced. Alternatively, during the same acquisition time, images
at higher resolution can be obtained. Functional MRI and MR
spectroscopy benefit particularly from high magnetic fields.
Stable poly(amino carboxylate) complexes of Gd3þ are widely
used to enhance image contrast in MRI (2–4). In the last two
decades, much effort has been devoted to the improvement of
the efficacy of these contrast agents, by modifying the
microscopic parameters of the Gd3þ chelates via an appropriate
ligand design. For instance, the optimization of the rotational
motion by applying slowly tumbling macromolecular complexes
led to a considerable relaxivity increase in the intermediate field
range, as compared with the commercial, small molecular weight
agents GdDTPA or GdDOTA. Typically, these macromolecular
chelates have a high proton relaxivity peak centred between 20
and 60MHz. Above this frequency, their longitudinal relaxivity
strongly vanishes with increasing field, and at high fields very
slow rotation is not beneficial any more for relaxivity. Indeed, the
Solomon–Bloembergen–Morgan theory of paramagnetic relax-
ation (5) predicts that at frequencies above 200MHz the
relaxivity increases with the inverse of the rotational correlationSchematic representation of Gd3L.
edia Mol. Imaging 2008, 3 78–85 Copyright # 2008time tR, in contrast to that at lower frequencies, where it is
proportional to tR. Consequently, at very high fields intermediate
size molecules are favorable over very large ones. Recently we
have reported a self-assembled metallostar system with
remarkably high in vitro relaxivities at 200 and 400MHz (6,7).
The high efficacy of the metallostar has also been confirmed
under in vivo conditions in mice in a comparative MRI study (8).
The signal enhancement in the inversion recovery fast low angle
shot (IR FLASH) images after the injection of the metallostar at
0.05mmol Gd kg1 body weight (BW) was considerably higher
than after GdDOTA injection (at 0.1mmol Gd kg1 BW), despite
the higher dose of the latter. The metallostar injection resulted in
a greater drop in the spin-lattice relaxation time (T1), as calculated
from the inversion recovery TrueFISP imaging (IR TrueFISP) data
for various tissues, than the GdDOTA injection. This study also
indicated similar pharmacokinetics for the metallostar and for
GdDOTA, involving fast renal clearance, a leakage to the extra-
cellular space in the muscle tissue and no leakage to the brain.
One drawback of the metallostar is the limited stability of
the Fe2þ-tris(bipyridine) core, leading to a slow decomposition in
biological conditions which might raise toxicity concerns (7). In
order to overcome this problem, a novel chelate, H12L, was
designed involving covalent linking of three DTTA units to a
central xylyl core (DTTA4¼diethylene-triamine-tetraacetate).
The ligand H12L forms a trinuclear Gd
3þ complex, Gd3L, (Fig. 1)
which has the appropriate, intermediate size to attain high
relaxivities at 4.7–9.4 T. The synthesis of the ligand and the
physico-chemical characterization of the Gd3þ complex have
been reported elsewhere (9). The in vitro measurements showed
that the Gd3L complex indeed has considerably higher r1 values
at high field as compared with the commercial agents (Table 1).
At 400MHz and 378C, its relaxivity is three times superior to that
of GdDOTA (10.2 vs 3.0mM1 s1). In addition to the appropriate
size of the complex, the presence of two inner sphere water
molecules and their efficient exchange rate are also important
factors to contribute to this remarkable relaxivity (9).Table 1. High field relaxivities of selected Gd3þ complexes
measured in water (pH 7.4)
r1 (mM
1 s1)
200MHz (4.7 T) 400MHz (9.4 T)
258C 378C 258C 378C
Gd3L 17.0 14.1 10.7 10.2
Metallostara 16.4 15.8 9.3 8.5
GdDOTAa 4.0 3.0 3.9 3.0
GdDTPA 4.2 3.2 4.1 3.1
aLivramento et al. (8).
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0Here we report an in vivo MRI feasibility study at 9.4 T
using Gd3L as a potential MRI contrast agent dedicated to high
magnetic fields. The pharmacokinetics and in vivo relaxivity were
assessed in mice and compared with those of a typical
commercial, small molecular weight contrast agent, GdDOTA.
The MRI results have been complemented with dynamic
scintigraphic and biodistribution studies in Wistar rats at short
(10–15min) and long (24 h) periods of time by using the
153Sm analog compound, 153Sm3L.2. RESULTS AND DISCUSSION
2.1. Magnetic resonance imaging
Comparative MRI studies have been performed at 9.4 T in mice
with Gd3L and GdDOTA. Gd3Lwas well tolerated by the animals at
the dose of 8mmol Gd kg1 BW. No gross side effects were
observed during the injection, immediately or several days after
the experiment. During the experiment, the respiration of the
animal was continuously monitored. In the first minute
post-injection, a drop in the respiration frequency was detected.
The values returned to the pre-injection level after a few minutes.
Overall, Gd3L seemed to be harmless to the animals; nevertheless,
a more detailed study would be required to further assess its
toxicology.
The toxicity of novel Gd3þ complexes to be tested in in vivo
experiments is an important concern. The Gd3þ chelate has to be
sufficiently stable to avoid any Gd3þ release before total excretionFigure 2. Representative series of dynamic contrast enhanced images after G
(first four images), kidney structures (cortex, inner and outer medulla) and ad
marked change of signal intensity was observed in the vascular system (ar
enhancement in the renal cortex and later in the medulla. A slight enhance
www.interscience.wiley.com/journal/cmmi Copyright # 20of the contrast agent from the body. This requires sufficient
thermodynamic stability and kinetic inertness of the complex
(10). Thermodynamic stability was assessed for various GdDTTA-
type complexes and showed a limited decrease as compared
with GdDTPA. The stability constants determined for the Gd3þ
complexes formed with DTTA-derivative chelators were
logKGdL¼ 17–19, with corresponding pGd values of 15–16
([L]total¼ 10mM; [Gd]total¼ 1mM; pH 7.4) (7,11). These pGd values
are very similar to that of GdDTPA-BMA (pGd¼ 15.8), one of the
clinically approved contrast agents (12). Nevertheless, we are
aware that Gd3L is just a model system and cannot be proposed
for in vivo human applications. Recently, the lack of high kinetic
inertness of certain Gd3þ complexes, in particular GdDTPA-BMA,
has been recognized to be associated with the potentially lethal
nephrogenic systemic fibrosis/nephrogenic fibrosing dermopa-
thy (NSF/NFD). We have to note, however, that only patients with
severe renal failure develop NSF; those who present a very slow
excretion of the agent from the body. On the other hand,
high-field imaging is primarily used in small animal studies and
not for human applications. In small animals the excretion is
much more rapid, and therefore the kinetic inertness of the
complex is less critical.
2.2. DCE experiments
Figure 2 shows a representative series of dynamic contrast
enhanced (DCE) images after Gd3L and GdDOTA injections at the
same dose of 8mmol Gd kg1 BW. In the pre-injection image,d3L injection at a dose of 8mmolGd kg
1 BW. In the pre-injection images
jacent tissues were dark due to the particular inversion delay chosen. A
tery aorta and vein cava) just after bolus injection, followed by a signal
ment in the muscle and liver was also observed; B¼ 9.4 T.
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Figure 3. Dynamic contrast enhanced images after GdDOTA and
Gd3L injections at the dose of 8mmol Gd kg
1 BW each. For both agents,
marked changes of signal intensity were observed in the vascular system,
renal cortex and medulla. At 10min post-injection the signal enhance-
ment observed after Gd3L injection is considerably higher as compared
with the GdDOTA injection, despite the identical dose of the two agents
used; B¼ 9.4 T.
Figure 4. Relaxation rates, DR1, calculated from the IR TrueFISP data
after GdDOTA (top) and injection Gd3L (bottom) for three different regions
of interest: kidney cortex, kidney medulla and the vascular system. During
the excretory phase (time> 4min), DR1 for renal tissues was similar
for Gd3L and GdDOTA when the latter was injected at a dose three times
higher (24mmolGd kg1 BW). The time courses represent mean values of
n¼ 6 animals. Symbols: (solid squares) cortex; (solid circles) medulla;
(solid triangles) vascular system (cava); B¼ 9.4 T.
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8kidney structures (cortex, inner and outer medulla) and adjacent
tissues were dark due to the particular inversion delay chosen.
For both agents, marked changes of signal intensity were
observed immediately after bolus injection in the vascular system
(artery aorta and vena cava), followed by a signal enhancement in
the renal cortex and later in the medulla (Fig. 3). A slight
enhancement in the muscle and liver was also observed for both
contrast agents (CAs). At 10min post-injection, during the
renal excretory phase, the signal enhancement observed
after Gd3L injection was considerably higher as compared with
the GdDOTA injection, despite the identical dose of the two
agents used. This finding is in accordance with the remarkably
higher relaxivity of Gd3L determined in vitro.
2.3. T1 experiments
The time course of the relaxation rates (DR1 –– R1 R10¼ 1/T1 1/
T10), calculated from the IR TrueFISP data, is shown in Fig. 4. The
increase in the relaxation rate is supposed to be directly
proportional to the concentration of the contrast agent delivered
to the tissue, if saturation effects are absent. If in vitro CA
relaxivities (Table 1) and DR1 curves (Fig. 4) are used to estimate
the local concentration in the kidney tissues and blood, the Gd
concentration calculated is 3 times higher for GdDOTA. This
result is consistent with the experimental setup (mice have
received a three-fold dose of GdDOTA).
The pharmacokinetics was found to be similar for Gd3L and
GdDOTA. Both CAs are primarily eliminated by the kidneys from
the blood stream. These finding is in full accordance with
previous reports on the pharmacokinetics of the GdDOTA (13–15)
or other small molecular weight Gd-based contrast agents (14).
For both CAs, the vascular response was characterized by
a sharp maximum 10 s after the bolus injection followed by a
rapid elimination from the blood. The cortex and medullaContrast Media Mol. Imaging 2008, 3 78–85 Copyright # 2008showed a similar clearance pattern, with a slower rate for
medulla. As the elimination rate depends on the dose
administered (15), the elimination curves observed for GdDOTA
are slightly different from those described in Livramento et al. (8)
as a consequence of the lower dose used here. For both CAs, the
elimination curve approached a steady-state 3min after
injection (a slowly descending segment, corresponding to the
predominant excretory function).
For both CAs, the IR-TrueFISP experiment was not sensitive
enough to detect T1 changes in the muscles and liver (data not
shown), probably due to the weak dose used and/or the very
short T2 found in these tissues.
It has been shown previously that the in vitro and in vivo
relaxivities of Gd-based contrast agents can be significantly
different, the latter being affected by the tissue structure and
physiology (16,17). It has been demonstrated that GdDTPA has
considerably lower relaxivities in the rat kidney cortex or medulla
than measured in saline solution or in other tissues, which is
related to the compartmentalization of the contrast agent in the
kidney (18,19). Evidently, the quantitative determination of the
in vivo relaxivity of a contrast agent requires knowledge of its
local concentration. In some cases, this concentration has beenJohn Wiley & Sons, Ltd. www.interscience.wiley.com/journal/cmmi
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2obtained by independent measurements. These studies, how-
ever, are not without difficulties, since they often induce
significant perturbations to the tissues by studying intact excised
tissues (20), making measurements post-mortem (18) or ensuring
a constant infusion of the contrast agent in order to establish a
steady state concentration (19). In the absence of such
experiments, only an estimation of the relative in vivo relaxivity
can be performed if we assume similar pharmacokinetics for
GdDOTA and Gd3L. In this case, the relative in vivo relaxivity
of Gd3L as compared with that of GdDOTA can be obtained by:
r1ð ÞGd3L
r1ð ÞGdDOTA
¼ doseð ÞGdDOTA
doseð ÞGd3L
 DR1ð ÞGd3L
DR1ð ÞGdDOTA
: (1)
For the sake of simplicity, if CA relaxivities are compared for the
period of the excretory phase (a slowly descending segment,
starting 3min post-injection, corresponding to the predomi-
nant excretory function), DR1 for various tissues was similar
for Gd3L and GdDOTA, when the latter was injected at a dose
three times higher (24mmol Gd kg1 BW). Table 2 summarizes
the variation of DR1 across different regions of the kidney
after Gd3L and GdDOTA injection, during the excretory phase. No
significant (p< 0.01) differences were found between the DR1
values measured for the two different contrast agents, despite
the different doses applied. Using the averageDR1 values given in
Table 2 and taking into account the 3-fold higher dose of
GdDOTA, we find that the in vivo r1 for Gd3L is approximately
three times higher than for GdDOTA.
The renal clearance, based on the observation of the DR1
values in the three different regions of interest (kidney cortex,
kidney medulla and the vascular system), was similar to that
previously reported for the metallostar compound (8) and for
other small-molecular-weight Gd-based contrast agents (13,14).
As the high DR1 values of the kidney medulla show, Gd3L is
predominantly eliminated from the blood stream by the kidneys,
analogously to GdDOTA or to other small chelates. Furthermore,
as expected on the basis of its relatively small size, Gd3L does not
function as a blood pool agent.
Clearly, we do not have any evidence on the identical
biodistribution of GdDOTA and Gd3L. As explained above, the
quantitative assessment of the in vivo contrast agent concen-
tration can be only achieved via very invasive methods, which
were beyond the scope of this study. In order to proceed in the
most cautious way, the comparison of the relaxivity of the two
compounds was done in the excretory phase where the
experimentally measured relaxation rates attain a very slowly
descending segment. In this quasi-stationary phase, different
pharmacokinetic behavior has less influence on the comparison.
We believe that the fact that the relaxivity ratio calculated is close
to what is found in vitro is probably not a coincidence. Also, theTable 2. Average DR1 values (n¼ 6, mean SD) in various
kidney regions during the excretory phase; B¼ 9.4 T
Region
DR1 (s
1)
Gd3L;
8mmol kg1 BW
DR1 (s
1)
GdDOTA;
24mmol kg1 BW
Kidney cortex 0.43 0.07 s1 0.49 0.07 s1
Kidney medulla 0.71 0.19 s1 0.64 0.20 s1
Aorta/cava 0.19 0.05 s1 0.25 0.05 s1
www.interscience.wiley.com/journal/cmmi Copyright # 20time-dependent relaxation rates measured in the blood (Fig. 4,
blue curves) seem to indicate that the rate of elimination of the
agent from the blood is very similar for the two compounds.
Furthermore, the high relaxation efficiency of Gd3L under
in vivo conditions suggests that the two inner sphere water
molecules are not (or not substantially) replaced by endogenous
anions or other potential donors from proteins, etc., in the
biological medium. The same observation was made in the animal
imaging experiments previously performed with the metallostar
compound, containing an identical DTTA chelator to complex
Gd3þ. This finding is very important and favors the DTTA chelates
in comparison to the macrocyclic bishydrated DO3A-type Gd3þ
complexes, which tend to form ternary complexes with a variety
of endogenous carboxylate donors (21).
2.4. Biodistribution and dynamic scintigraphic studies
In order to gain further insight into the in vivo behaviour of the
trinuclear Gd3L, we performed biodistribution and dynamic g
scintigraphic studies in Wistar rats using the Sm3þ analog
complex where the gadolinium was replaced by a mixture of
radioactive (153Sm) and non-radioactive samarium (22,23).
The scintigraphic image obtained 200 s after tracer injection of
Sm*3L is shown in Fig. 5. As this figure shows, and in full
accordance with the MRI findings, the main activity is located in
the kidneys and the bladder, which represent the typical
excretion pathway for such a small and hydrophilic complex. A
rapid clearance from all other organs is also observed. The
time–activity curves, obtained from the dynamic acquisition
experiments, are shown in Fig. 6. The curves were smoothed and
normalized in relation to the maximum activity obtained. The
clearance of the compound via the kidneys was confirmed again.
The liver–spleen curve was similar to the thorax curve,
corresponding only to blood activity.
The characteristics of the renal clearance and washout of
Sm*3L were further investigated by biodistribution studies in
Wistar rats. The results obtained at 15min and 24 h post-injectionFigure 5. Scintigraphic dynamic image obtained 200 s after intravenous
injection of 153Sm3L in a Wistar rat. This figure is available in colour online
at www.interscience.wiley.com/journal/cmmi
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Figure 6. Time–activity curves obtained from dynamic scintigraphic images for the various regions of interest. The y-axis represents the normalized
activity. This figure is available in colour online at www.interscience.wiley.com/journal/cmmi
Figure 7. Biodistribution, stated as percentage of injected dose per gram of organ (%ID/g SD), of 153Sm3L in Wistar rats: (a) 15min and (b) 1 h after
intravenous injection. Results are the mean values of four animals.
MRI CONTRAST AGENTS FOR HIGH FIELD APPLICATIONSare summarized in Fig. 7. At 15min, the activity is overwhelmingly
localized in the urine (% ID g1 in urine¼ 10.0 5.12), which is in
agreement with what was observed in the scintigraphic
experiments. As expected, at 24 h after injection the activity
dramatically decreased in all organs with the exception of the
liver. The reason for such activity in the liver is still not clear. In the
first instance it could probably be attributed to some later metal
decomplexation; however if that was the case the activity value in
the spleen and femur should also corroborate such an increase,
which is not all observed.83. CONCLUSIONS
Given its appropriate size and the corresponding rotational
dynamics, Gd3L has remarkable proton relaxivities at high
magnetic field and is a prime candidate for CA applications in
small animal MR imaging at high fields. MRI studies performed at
9.4 T in mice indicated that the in vivo r1 relaxivity of Gd3L is
approximately three times higher than that of GdDOTA. The
pharmacokinetics is similar for Gd3L and GdDOTA, both following
fast renal clearance in mice. Dynamic scintigraphic studies
performed in rats using Sm3L with
153Sm enrichment are in
accordance with this elimination pathway. The biodistributionContrast Media Mol. Imaging 2008, 3 78–85 Copyright # 2008results obtained at 15min and 24 h post-injection gave further
support to the scintigraphic and MRI results.4. EXPERIMENTAL
153-Samarium chloride (153SmCl3) was produced at the ITN
(Instituto Tecnolo´gico e Nuclear), Lisbon, with a specific activity
>5GBqmg1. For this purpose a 153Sm2O3 was prepared from a
98% samarium-152 enriched samarium oxide target, sealed into a
quartz vial and welded into an aluminum can, by neutron
irradiation using a thermal flux of 2.3 1013 n cm2 s1. Follow-
ing irradiation, the sample was opened, dissolved in HCl (1 M) and
the final 153-samarium chloride (153SmCl3) was brought to a
stock concentration of 1.9mM.
4.1. Sample preparation
AGdCl3 solution was prepared from Gd2O3 of 99.9% purity (Fluka)
by dissolution in excess HCl, which was evaporated off. The
concentration of the metal ion was determined by complexo-
metric titration with standardized Na2H2EDTA solution. The
synthesis of the ligand H12L has been described previously
(9). Gd3L was prepared by adding solid ligand to a solution ofJohn Wiley & Sons, Ltd. www.interscience.wiley.com/journal/cmmi
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4GdCl3 in 1:3 ligand to metal molar ratio. The pH, measured with a
calibrated combined glass electrode, was adjusted to 7.1 by
addition of known amounts of NaOH (0.1 M). The absence of free
metal was checked by the xylenol orange test.
Sm3L was prepared by adding a ligand solution (pH 6.8) to a
solution of SmCl3 (Sigma-Aldrich), where the concentration of
the metal ion was determined by complexometric titration
with standardized Na2H2EDTA solution. A solution of
153SmCl3
(74MBq) was then added to the previous solution to reach 3:1
overall metal:ligand ratio.
4.2. Animals
MRI studies were performed in agreement with the French
guidelines for animal care and in compliance with procedures
approved by the appropriate institutional review committees.
In vivo experiments were performed in male FVB/N mice (8–10
weeks, 24–26 g, obtained from Janvier Laboratories, Le Genest-
St-Isle, France). All animals were kept in an animal housing facility,
and given ad libitum access to food and water.
4.3. CA injection
Gd3L (10mM) was injected in mice as a bolus via a tail vein
catheter at a dose of 8mmol Gd kg1 body weight. For com-
parison, the experiments were repeated with injection of the
small molecular weight contrast agent gadolinium(III)-1,4,
7,10 tetraazacyclododecane-1,4,7,10-tetraacetate ([Gd(DOTA)
(H2O)]¼GdDOTA) (Dotarem, Guerbet, France).
The in vitro r1 relaxivity at 9.4 T was approximately 3 times
larger for Gd3L than for GdDOTA (9). Thus, in the experiments
where T1 was measured, one group of mice received GdDOTA
(30mM) at a dose of 24mmol Gd kg1 BW (high dose). A lower
dose (8mmol Gd kg1 BW, 10mM) of GdDOTAwas also used in the
DCE experiments for the sake of comparison.
4.4. MRI
MRI experiments were carried out in a horizontal 9.4 T Bruker
Biospec MR system (Bruker Biospin, Wissembourg, France)
equipped with gradients capable of switching 950mTm1 in
50ms. A 12-element linear birdcage coil (Bruker Biospin) with
inner diameter 35mm and length 60mm was used to achieve
uniform excitation and reception.
A custom-built holder was used to fix the animals in the supine
position into the birdcage coil. The mice were anesthetized with
isoflurane (1.5–2.5%) in an O2–N2O 1:1 mixture applied with a
face mask allowing free breathing. Respiration was monitored
using a balloon taped to the thorax and connected to a pressure
transducer (SA Instruments, Inc., Stony Brook, NY, USA). The mice
body temperature was monitored with a rectal thermo-sensor
and kept at 37 0.58C throughout the experiment, using a plastic
tube with circulating warm water positioned around their bodies.
4.4.1. DCE experiments
Regional contrast agent uptake was assessed using dynamic
contrast enhanced (DCE) MRI. DCE experiments were carried out
using a series of 100 inversion-recovery TrueFISP coronal images
(1.5mm thick) of mouse kidneys with an inversion delay of 1.5 s.
This inversion time value corresponds to the ‘nulling point’ for the
medulla kidney (T1 renal medulla> T1 renal cortex). After
adiabatic inversion one image was acquired with the followingwww.interscience.wiley.com/journal/cmmi Copyright # 20parameters: TR/TE¼ 2/1ms, at 250 kHz readout bandwidth,
0.95ms hermite 608 excitation pulse, field-of-view (FOV)¼
50 23mm, matrix¼ 128 96. The acquisition time for this
image was 291.2ms. Temporal resolution (i.e. time period
between the start of two successive images) was 20 s before
CA injection and 6 s thereafter. The overall experimental duration
was 12min.
4.4.2. In vivo T1 time course measurements
T1 measurements were performed using a series of continuous
inversion recovery TrueFISP (24) images with the following
parameters: TE¼ 1ms, TR¼ 2ms, flip angle¼ 608, number of T1
blocks¼ 80, range of inversion time (TI)¼ 63.6–5158.9ms, TI
increment (i.e. acquisition time for one frame)¼ 145.58ms,
number of frames¼ 36. Bolus injection of the contrast agents,
flushed with 200ml of saline, was carried out immediately after
the sixth IR block. A delay was introduced between the start
of two successive blocks to allow for longitudinal relaxation before
the next inversion. The temporal resolution (i.e. time period
between the start of two successive blocks, or TRblock) was 20 s
before CA injection and 8 s thereafter; FOV¼ 50mm 23mm,
matrix¼ 64 48, 1 coronal slice, slice thickness¼ 1.5mm. The
overall experimental duration was 12min.
4.5. MRI data processing
4.5.1. T1 mapping
Image analysis and processing were performed with the public
domain software ImageJ (NIH, http://rsb.info.nih.gov/ij) and
MATLAB (Mathworks Inc., Natick, MA, USA). T1 maps were
performed for each time point on a pixel-by-pixel basis from each
image using the following model function (24):
SðtÞ ¼ Sstst 1 INV  expðt=T1Þ½  (2)
where S(t) is the signal time course (following an inversion pulse)
and Sstst denotes the steady state signal for large inversion times
t. INV, the inversion factor, is also dependent on relaxation times
and is related to the relation between the initial inverted
magnetization and the steady-state signal (24). The apparent
spin-lattice relaxation time T1* describes the dynamic of the
signal recovery to Sstst. If off-resonance effects may be neglected,
the following formula relates the fitting parameters of eqn (1) to
the longitudinal relaxation time (24):
T1 ¼ T1 cosðu=2ÞðINV  1Þ; (3)
where u is the excitation angle.
Regions of interest (ROIs) corresponding to the kidney cortex
andmedulla, and vascular system, were first drawn on anatomical
images and then copy-pasted in the T1 maps. The time course of
the relaxivity rates (DR1 =– R1  R10¼ 1/T1  1/T10) was calculated
for these ROIs (T10 and T1 are the spin-lattice relaxation values
pre- and post-contrast agent injection, respectively).
4.6. Biodistribution and dynamic scintigraphic studies
A g camera-computer system (GE 400 GenieAcq, from General
Electric, Milwaukee, USA) was used for acquisition and
pre-processing. Data processing and display were performed
on a personal computer using software developed for the IDL 5.2
computer tool. A well counter (DPC-Gamma C12, LA, USA) with a08 John Wiley & Sons, Ltd. Contrast Media Mol. Imaging 2008, 3 78–85
MRI CONTRAST AGENTS FOR HIGH FIELD APPLICATIONSCompaq DeskPro compatible computer was used for activity
counting in the biodistribution studies.
Gamma images were obtained and biological distribution of
the 153Sm3L complex was determined using 200 g Wistar rats. All
animal studies were carried out in compliance with procedures
approved by the appropriate institutional review committees.
Conscious rats were allowed free access to food and water.
Four animals were anaesthetized with ketamine (50mgml1)-
chloropromazine (2.5%) (10:3) and injected in the femoral vein
with 200mCi of Sm*3L. The animals were then positioned in
dorsal decubitus over the detector. Image acquisition was
initiated immediately before radiotracer injection. Sequences of
120 images (of 5 s each), were acquired to 64 64 matrices.
Images were subsequently processed using an IDL based
program (Interactive Data Language, Research Systems, Boulder,
CO, USA).
In order to analyze the transport of the radiotracer over time,
four regions of interest (ROI) were drawn on the image files,
corresponding to the thorax, liver, left kidney and bladder. The
time–activity curves were obtained from these regions. Animals
were sacrificed 15min after injection and the majors organs
removed were weighted and counted in a g well-counter. Similar
biodistribution studies with a group of four rats sacrificed 24 h
after intravenous injection of 153Sm3L were also performed.Acknowledgements
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